SEC Form 4 · accession 0001638599-17-000130
Lipocine Inc. · LPCN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mahesh V. Patel
Officer — President and CEO · Director
Period of report
Jan 26, 2017
Accepted (ET)
Jan 30, 2017 · 9:41 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001535955
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitF1,F2 | $0.00 | Jan 26, 2017 | A | 60,000 | A | Dec 31, 2017 | Jan 25, 2027 | Common Stock | 60,000 | 60,000 | D |
Explanation of responses
- F1Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit
- F2Subject to vesting whereby 1/4 of the shares subject to the award will vest on December 31, 2017 and the remaining 3/4 of the shares subject to the award will vest on the receipt by the Company of FDA approval of LPCN 1021.